Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease

American Journal of Gastroenterology

Volumn 106, Issue 8, 2011, Pages 1419-1425

  Kahrilas, Peter J ^a   Howden, Colin W ^a   Hughes, Nesta ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b OXFORD PHARMAGENESIS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CISAPRIDE; ESOMEPRAZOLE; LANSOPRAZOLE; METOCLOPRAMIDE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; RABEPRAZOLE; RANITIDINE;

ARTICLE; DRUG RESPONSE; EMBASE; ESOPHAGEAL PH MONITORING; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MEDLINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; VISUAL ANALOG SCALE;

CONTROLLED CLINICAL TRIALS AS TOPIC; GASTROESOPHAGEAL REFLUX; HEARTBURN; HISTAMINE H2 ANTAGONISTS; HUMANS; PERISTALSIS; PROTON PUMP INHIBITORS; RESEARCH DESIGN; TREATMENT OUTCOME; VOMITING;

EID: 79961032230     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.146     Document Type: Article

References (42)

1. Vakil N, Veldhuyzen van Zanten S, Kahrilas P et al. The Montreal definition and classification of gastro-esophageal reflux disease (GERD)-a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-20.
2. van Pinxteren B, Numans ME, Bonis PA et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev; 18 October 2004;(4) CD002095.
3. El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 2010; 32: 720-37.
4. Khan M, Santana J, Donnellan C et al. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev; 18 April 2007;(2) CD003244.
5. Bochenek WJ, Mack ME, Fraga PD et al. Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. Aliment Pharmacol Ther 2004; 20: 1105-14. (Pubitemid 39657944)
6. Sontag SJ, Hirschowitz BI, Holt S et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the US Multicenter Study. Gastroenterology 1992; 102: 109-18.
7. Robinson M, Decktor DL, Maton PN et al. Omeprazole is superior to ranitidine plus metoclopramide in the short-term treatment of erosive oesophagitis. Aliment Pharmacol Ther 1993; 7: 67-73. (Pubitemid 23053390)
8. Corinaldesi R, Valentini M, Belaiche J et al. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study. Aliment Pharmacol Ther 1995; 9: 667-71. (Pubitemid 26042104)
9. Lauritsen K, Devi è re J, Bigard MA et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: metropole study results. Aliment Pharmacol Ther 2003; 17: 333-41. (Pubitemid 36259395)
10. Richter JE, Peura D, Benjamin SB et al. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med 2000; 160: 1810-6. (Pubitemid 30418819)
11. Kahrilas PJ, Miner P, Johanson J et al. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. Dig Dis Sci 2005; 50: 2009-18. (Pubitemid 41504082)
12. Hemmink GJ, Bredenoord AJ, Weusten BL et al. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: " on " or " off " proton pump inhibitor? Am J Gastroenterol 2008; 103: 2446-53.
13. Eggleston A, Katelaris PH, Nandurkar S et al. Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care-prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg. Aliment Pharmacol Ther 2009; 29: 967-78.
14. Bate CM, Griffin SM, Keeling PW et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 1996; 10: 547-55. (Pubitemid 26254798)
15. Fass R, Murthy U, Hayden CW et al. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000; 14: 1595-603. (Pubitemid 32011733)
16. Pai VG, Pai NV, Th acker HP et al. Comparative clinical trial of S-pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease. World J Gastroenterol 2006; 12: 6017-20. (Pubitemid 44608481)
17. Pai V, Pai N. Randomized, double-blind, comparative study of dexrabeprazole 10 mg versus rabeprazole 20 mg in the treatment of gastroesophageal reflux disease. World J Gastroenterol 2007; 13: 4100-2. (Pubitemid 47323164)
18. Mine S, Iida T, Tabata T et al. Management of symptoms in step-down therapy of gastroesophageal reflux disease. J Gastroenterol Hepatol 2005; 20: 1365-70. (Pubitemid 43960833)
19. Juul-Hansen P, Rydning A, Jacobsen CD et al. High-dose proton-pump inhibitors as a diagnostic test of gastro-oesophageal reflux disease in endoscopic-negative patients. Scand J Gastroenterol 2001; 36: 806-10. (Pubitemid 32656554)
20. Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastrooesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997; 11: 765-73. (Pubitemid 27376366)
21. Havelund T, Laursen LS, Skoubo-Kristensen E et al. Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial. Br Med J (Clin Res Ed) 1988; 296: 89-92. (Pubitemid 18047632)
22. Devault KR, Johanson JF, Johnson DA et al. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fift een milligrams. Clin Gastroenterol Hepatol 2006; 4: 852-9.
23. Gough AL, Long RG, Cooper BT et al. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 1996; 10: 529-39. (Pubitemid 26254796)
24. Hetzel DJ, Dent J, Reed WD et al. Healing and relapse of severe peptic esophagitis aft er treatment with omeprazole. Gastroenterology 1988; 95: 903-12.
25. Richter JE, Bochenek W. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. Am J Gastroenterol 2000; 95: 3071-80.
26. Johnsson F, Hatlebakk JG, Klintenberg AC et al. Symptom-relieving effect of esomeprazole 40 mg daily in patients with heartburn. Scand J Gastroenterol 2003; 38: 347-53. (Pubitemid 36606303)
27. Koop H, Schepp W, Dammann HG et al. Comparative trial of pantoprazole and ranitidine in the treatment of reflux esophagitis. Results of a German multicenter study. J Clin Gastroenterol 1995; 20: 192-5.
28. Kaspari S, Biedermann A, Mey J. Comparison of pantoprazole 20 mg to ranitidine 150 mg b.i.d. in the treatment of mild gastroesophageal reflux disease. Digestion 2001; 63: 163-70. (Pubitemid 32429731)
29. van Rensburg CJ, Honiball PJ, Grundling HD et al. Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis. Aliment Pharmacol Ther 1996; 10: 397-401. (Pubitemid 26173889)
30. Chey W, Huang B, Jackson RL. Lansoprazole and esomeprazole in symptomatic GERD: A double-blind, randomised, multicentre trial in 3000 patients confirms comparable symptom relief. Clin Drug Investig 2003; 23: 69-84. (Pubitemid 36286708)
31. Korner T, Schutze K, van Leendert RJ et al. Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study. Digestion 2003; 67: 6-13. (Pubitemid 36570296)
32. Wong WM, Lai KC, Hui WM et al. Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastrooesophageal reflux disease. Aliment Pharmacol Ther 2004; 19: 455-62. (Pubitemid 38297115)
33. Mossner J, Holscher AH, Herz R et al. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment Pharmacol Ther 1995; 9: 321-6.
34. Dehn TC, Shepherd HA, Colin-Jones D et al. Double blind comparison of omeprazole (40 mg od) versus cimetidine (400 mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH monitoring. Gut 1990; 31: 509-13. (Pubitemid 20185949)
35. Mulder CJ, Dekker W, Gerretsen M. Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial). Dutch Study Group. Eur J Gastroenterol Hepatol 1996; 8: 1101-6. (Pubitemid 26383869)
36. Holtmann G, Bytzer P, Metz M et al. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastrooesophageal reflux disease. Aliment Pharmacol Ther 2002; 16: 479-85. (Pubitemid 34214527)
37. Kahrilas PJ. When proton pump inhibitors fail. Clin Gastroenterol Hepatol 2008; 6: 482-3.
38. Zerbib F, Duriez A, Roman S et al. Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors. Gut 2008; 57: 156-60. (Pubitemid 351158039)
39. Patient-reported outcome measures: use in medical product development to support labeling claims Rockville, USA: Food and Drug Administration. 2009 Available from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf (Accessed 9 December 2009).
40. McColl E, Junghard O, Wiklund I et al. Assessing symptoms in gastroesophageal reflux disease: how well do clinicians ' assessments agree with those of their patients? Am J Gastroenterol 2005; 100: 11-8. (Pubitemid 41623262)
41. Shaw MJ, Talley NJ, Beebe TJ et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001; 96: 52-7. (Pubitemid 32104807)
42. Dent J, Kahrilas PJ, Hatlebakk J et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol 2008; 103: 20-6.